Suchergebnisse - "Subramanian, Sreedhar"

PubPharm (10)

1

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE) : a multicentre, open-label randomised controlled trial

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Noor, N. | Lee, J. | Bond, S. | +40

2

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13] : A Multicentre Cohort Study

enthalten in: Journal of Crohn's & colitis | 2022

von Smith, P. | Critchley, L. | Storey, D. | +17

3

From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease : a pandemic-driven initiative

enthalten in: The lancet. Gastroenterology & hepatology | 2021

von Verma, A. | Patel, A. | Subramanian, S. | +1

4

Immune checkpoint inhibitor-related colitis assessment and prognosis : can IBD scoring point the way?

enthalten in: British journal of cancer | 2020

von Cheung, V. | Gupta, T. | Olsson-Brown, A. | +16

5

Long-term Outcomes of Paediatric Patients Admitted With Acute Severe Colitis- A Multicentre Study From the Paediatric IBD Porto Group of ESPGHAN

enthalten in: Journal of Crohn's & colitis | 2019

von Krauthammer, A. | Tzivinikos, C. | Assa, A. | +31

6

Editorial : accelerated infliximab induction-it's time to settle the debate! Authors' reply

enthalten in: Alimentary pharmacology & therapeutics | 2019

von Sebastian, S. | Kennedy, N. | Subramanian, S. | +1

CommentOn: Aliment Pharmacol Ther. 2019 Sep;50(6):675-683. - PMID 31456297

7

Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis

enthalten in: European journal of gastroenterology & hepatology | 2019

von Davis, R. | McParland, P. | Dodd, S. | +8

8

Recent advances in clinical practice : a systematic review of isolated colonic Crohn's disease: the third IBD?

enthalten in: Gut | 2017

von Subramanian, S. | Ekbom, A. | Rhodes, J.

9

Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels

enthalten in: European journal of gastroenterology & hepatology | 2016

von Bond, A. | Asher, R. | Jackson, R. | +6

10

Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent

enthalten in: Inflammatory bowel diseases | 2011

von Subramanian, S. | Yajnik, V. | Sands, B. | +2

1
[1]